OncoMatch/Clinical Trials/NCT07006506
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Is NCT07006506 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Belumosudil for graft versus host disease.
Treatment: Belumosudil — The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Cannot have received: belumosudil
Lab requirements
Blood counts
engraftment: ANC ≥500/μL and platelets ≥ 20000/μL on 3 consecutive measurements (each occurring at least 1 day apart); no platelet transfusion within 7 days before the first measurement
Kidney function
glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2
Liver function
ALT and AST ≤ 3x upper limit of normal (ULN); total bilirubin ≤1.5 x ULN (unless benign congenital hyperbilirubinemia)
Engraftment is defined as ANC≥500/μL and platelets ≥ 20000/μL on 3 consecutive measurements (each occurring at least 1 day apart). The patient must not have had a platelet transfusion within 7 days before the first measurement. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x upper limit of normal (ULN). Total bilirubin ≤1.5 x ULN (unless benign congenital hyperbilirubinemia). Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07006506 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior belumosudil disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify